The NEJM [43] and other magazines have reported that the monoclonal antibody drug blocking immunoassay (such as PD-1 and PD-L1) is effective for treating non-small cell lung cancer, malignant melanoma, renal cell carcinoma, ovarian cancer, stomach cancer, and breast cancer. Here, CD274 is linked to non-small cell lung carcinoma.